Zacks Investment Research upgraded shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a hold rating to a buy rating in a report released on Monday. The firm currently has $4.50 price target on the biopharmaceutical company’s stock.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
Several other research firms also recently issued reports on AEZS. Maxim Group set a $2.00 price objective on shares of AEterna Zentaris and gave the company a buy rating in a research note on Thursday, December 20th. ValuEngine upgraded shares of AEterna Zentaris from a sell rating to a hold rating in a research note on Wednesday, January 2nd. Finally, HC Wainwright set a $3.00 price objective on shares of AEterna Zentaris and gave the company a buy rating in a research note on Thursday, December 20th. Four investment analysts have rated the stock with a buy rating, AEterna Zentaris currently has an average rating of Buy and an average target price of $3.17.
NASDAQ AEZS opened at $4.00 on Monday. AEterna Zentaris has a 1 year low of $1.12 and a 1 year high of $4.39. The firm has a market capitalization of $65.10 million, a price-to-earnings ratio of 12.38 and a beta of 1.23.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in AEterna Zentaris in the fourth quarter valued at $30,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of AEterna Zentaris during the fourth quarter worth about $66,000. Acadian Asset Management LLC boosted its stake in shares of AEterna Zentaris by 27.2% during the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 9,640 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of AEterna Zentaris during the third quarter worth about $101,000. Institutional investors own 15.29% of the company’s stock.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.